SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (5275)1/7/1998 6:58:00 PM
From: Vector1  Read Replies (2) | Respond to of 17367
 
PB,
My apologies to the thead if this has been discussed, but what is the common wisdom on the thread as to XOMA'a royalty rate on Rituxan sales by IDEC/GENE. I believe the sales level will be quite substantial and even a small single digit royalty (ie. 3%) could turn out to be significant for a company like XOMA
V1.



To: Pseudo Biologist who wrote (5275)1/7/1998 8:10:00 PM
From: mike head  Respond to of 17367
 
Pseudo B. In your research on TRMS... If you find anything on this "stealth" company, would you be so kind as to post it to the TRMS thread? Thanks, mch
(ref Jan 7 posting)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News